



This Trading Floor Research report is the weekly follow-up:

(Please, watch this list closely. If a TFR recommended stock does not appear in this list, it has been sold or was never bought)

- Remitly Global (RELY) was purchased on August 8. The stock is in a tight base above Fibonacci support at 24.27. The next Fibonacci target is at 27.18.
- **Denison Mines (DNN)** was purchased on August 21. The First Fibonacci target was hit today at 1.53, and ½ of the position was sold. Uranium and Uranium stocks look incredibly strong. The next Fibonacci target is at 1.67.



This Trading Floor Research report is the weekly follow-up:

(Please, watch this list closely. If a TFR recommended stock does not appear in this list, it has been sold or was never bought)

- Paymentus Holdings (PAY) was purchased on September 5. PAY is in the strong Software infrastructure industry group. It is in a tight base above Fibonacci support at 14.87. The next Fibonacci target is at 16.96.
- Direxion Daily TSLA Bear 1X (TSLS) was purchased on September 6. TSLA broke its ½ number earlier this week on a Morgan Stanley upgrade. I am giving the stock a few more days to close below its bear market ½ number at 258.16. The stock is finding resistance at the ¾ number of its July high to August low at 277.56. A close above 277.56 will be a sell signal for the TSLA position.
- **Direxion Daily GOOGL Bull 1.5X (GGLL)** was purchased on September 8. Alphabet Inc. (GOOGL) continues to show great strength in this market. The stock closed back above Fibonacci resistance at 135.87 today on solid accumulation. GGLL closed at 31.99. The next Fibonacci target on GGLL is at 33.66.



This Trading Floor Research report is the weekly follow-up:

(Please, watch this list closely. If a TFR recommended stock does not appear in this list, it has been sold or was never bought)

SPDR S&P Regional Banking ETF (KRE) October 20, 43 Puts were purchased today @ 1.55.

Direxion Small Cap Bear 3X (TZA) was purchased today at 28.13.




This Trading Floor Research report contains:

IGC Pharma Inc. (IGC)

Buy Candidate: IGC Pharma Inc. (IGC)

- Industry Group: Cannabis. The Cannabis stocks are seeing incredible accumulation. I see potential as these stocks break out of constructive bases with massive volume. No other industry group in the market is seeing this kind of accumulation.
- IGC Pharma Inc. (IGC) is a biopharmaceutical that develops cannabinoid-based formulations to treat Alzheimer's disease.
- IGC Pharma Inc. (IGC) broke out of a Cup-with-handle base two days ago. The stock is forming a high handle above Fibonacci support at .44.
- IGC Pharma Inc. (IGC) has formed a Long-Tail Down pattern on the point and figure chart. The three-box reversal will complete at .75.
- IGC Pharma Inc. (IGC) will give confirmation with a 30-minute close above .45 on above-average volume.
- Wait for text confirmation!
- Start Position at 1-star(*)
- •IGC Pharma Inc. (IGC) is under massive accumulation with an Up/Down Volume ratio of 2.07, breaking 100-day highs.
- IGC Pharma Inc. (IGC) closed at .446.
- IGC Pharma Inc. (IGC) VWAP is at 2.81.
- •Sell Fibonacci target prices: 1st target is .54; 2nd target is .70; 3rd target is .96
- •Stop sell price: Close below .38.


IGC Pharma Inc. (IGC)



Long-Tail Down pattern







The results are not (or may not be) representative of the performance of all selections made by Trading Floor Research (TFR) newsletter.

We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. TFR is providing information on this resource to you subject to the TFR "Terms and Conditions of Service" disclaimer.


Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice.





Disclaimer: The information, opinions and ideas expressed herein are for informational and educational purposes only and are based on research conducted and presented solely by the author. Nothing presented herein should be construed as investment advice, as an advertisement or offering of investment advisory services, or as an offer to sell or a solicitation to buy any security. The data presented herein were obtained from various third-party sources. While the data is believed to be reliable, no representation is made as to, and no responsibility, warranty or liability is accepted for the accuracy or completeness of such information. International investments are subject to additional risks such as currency fluctuations, political instability and the potential for illiquid markets. Past performance is no guarantee of future results. There is risk of loss in all trading. Back tested performance does not represent actual performance and should not be interpreted as an indication of such performance. Also, back tested performance results have certain inherent limitations and differs from actual performance because it is achieved with the benefit of hindsight.





Disclaimer

Before using this site, please make sure that you note the following important information:

Do your Own Research

Our content is intended to be used and must be used for informational purposes only. It is very important to do your own analysis before making any investment based on your own personal circumstances. You should take independent financial advice from a professional in connection with, or independently research and verify, any information that you find on our Website and wish to rely upon, whether for the purpose of making an investment decision or otherwise.

The content of this email is confidential and intended for the recipient specified in message only. It is strictly forbidden to share any part of this message with any third party, without a written consent of the sender. If you received this message by mistake, please reply to this message and follow with its deletion, so that we can ensure such a mistake does not occur in the future